What is it about?
a mechanism by which cancer cells acquire cisplatin resistance
Featured Image
Why is it important?
the c-MYC oncoprotein increases cisplatin resistance by decreasing production of the c-MYC inhibitor BIN1 (bridging integrator 1). The sensitivity of cancer cells to cisplatin depended on BIN1 abundance, regardless of the p53 gene status. BIN1 bound to the automodification domain of and suppressed the catalytic activity of poly(ADP-ribose) polymerase 1 (PARP1, EC 2.4.2.30), an enzyme essential for DNA repair, thereby reducing the stability of the genome.
Perspectives
a c-MYC-mediated positive feedback loop may contribute to cancer cell resistance to cisplatin. Bin 1 may be a biomaker to predict the sensitivity of cancer cells to cisplatin.
Dr Satoshi Tanida
Nagoya City university
Read the Original
This page is a summary of: c-MYC Suppresses BIN1 to Release Poly(ADP-Ribose) Polymerase 1: A Mechanism by Which Cancer Cells Acquire Cisplatin Resistance, Science Signaling, March 2011, American Association for the Advancement of Science,
DOI: 10.1126/scisignal.2001556.
You can read the full text:
Contributors
The following have contributed to this page
